thiazolyl blue and Animal Mammary Carcinoma
thiazolyl blue has been researched along with Animal Mammary Carcinoma in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Argano, M; Buracco, P; De Maria, R; Menzies, MPL; Rodlsberger, K | 1 |
| Batlle, A; Casas, A; Di Venosa, G; Fukuda, H | 1 |
| Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H | 1 |
Other Studies
3 other study(ies) available for thiazolyl blue and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Use of a colorimetric assay to evaluate the proliferation of canine mammary tumor cells exposed to propofol.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Colorimetry; Coloring Agents; Dog Diseases; Dogs; Female; Hypnotics and Sedatives; Mammary Neoplasms, Animal; Propofol; Tetrazolium Salts; Thiazoles | 2019 |
In vitro photosensitisation of a murine mammary adenocarcinoma cell line with Verteporfin.
Topics: Acridine Orange; Adenocarcinoma; Animals; Apoptosis; Coloring Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fluorescent Dyes; Light; Mammary Neoplasms, Animal; Mice; Microscopy, Fluorescence; Oxygen; Photosensitizing Agents; Porphyrins; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles; Time Factors; Tryptophan; Tumor Cells, Cultured; Verteporfin | 2002 |
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Hypoxia; Mammary Neoplasms, Animal; Mice; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2004 |